IL-17 inhibitors show no significant IBD risk increase in HS

A systematic review and meta-analysis of 24 studies (10 RCTs, 11 nonrandomized studies, 3 case reports) examined inflammatory bowel disease (IBD) incidence in patients with hidradenitis suppurativa (HS) treated with IL-17 inhibitors. Across RCTs, new-onset IBD occurred in 0.23% of treated patients versus none in placebo groups through week 16, with no significant difference in risk; nonrandomized studies showed a pooled incidence of 3.90%. The authors concluded that IBD events were rare and no significant increase in risk was observed with IL-17 inhibitors, though low event rates and inconsistent reporting limited interpretation.

Most relevant for: Patients with moderate to severe hidradenitis suppurativa being considered for or treated with IL-17 inhibitor therapy, particularly those with a personal or family history of inflammatory bowel disease.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.